Successful Treatment of a Patient with Multicentric Castleman's Disease who Presented with Thrombocytopenia, Ascites, Renal Failure and Myelofibrosis Using Tocilizumab, an Anti-Interleukin-6 Receptor Antibody

被引:54
作者
Kawabata, Hiroshi [1 ]
Kotani, Shin-ichi [1 ]
Matsumura, Yumi [2 ]
Kondo, Tadakazu [1 ]
Katsurada, Tatsuya
Haga, Hironori [3 ]
Kadowaki, Norimitsu [1 ]
Takaori-Kondo, Akifumi [1 ]
机构
[1] Kyoto Univ, Grad Sch Med, Dept Hematol & Oncol, Kyoto 6068501, Japan
[2] Kyoto Univ, Grad Sch Med, Dept Dermatol, Kyoto 6068501, Japan
[3] Kyoto Univ, Grad Sch Med, Dept Diagnost Pathol, Kyoto 6068501, Japan
关键词
Castleman's disease; systemic lupus erythematosus; interleukin-6; myelofibrosis; TAFRO syndrome; LYMPH-NODE HYPERPLASIA; DNA-SEQUENCES;
D O I
10.2169/internalmedicine.52.9482
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We herein describe an unusual case of multicentric Castleman's disease accompanied by thrombocytopenia, ascites, renal failure and myelofibrosis in a Japanese woman. The patient was initially diagnosed as having myelodysplastic syndrome with myelofibrosis. The general condition of the patient deteriorated rapidly; however, treatment with tocilizumab, an anti-interleukin-6 receptor antibody, together with corticosteroids dramatically improved her symptoms. The clinical features of this case were similar to those of three cases previously reported by Takai et al. (Rinsho Ketsueki, 2010, 51:320-5), which were determined to be thrombocytopenia, anasarca, fever, reticulin myelofibrosis and organomegaly (TAFRO) syndrome, a possibly distinct clinical entity.
引用
收藏
页码:1503 / 1507
页数:5
相关论文
共 16 条
  • [1] Mixed-type Multicentric Castleman's Disease Developing during a 17-year Follow-up of Sarcoidosis
    Awano, Nobuyasu
    Inomata, Minoru
    Kondoh, Keisuke
    Satake, Kohta
    Kamiya, Hiroyuki
    Moriya, Atsuko
    Ando, Tsunehiro
    Kumasaka, Toshio
    Takemura, Tamiko
    Takeuchi, Kengo
    Ikushima, Soichiro
    [J]. INTERNAL MEDICINE, 2012, 51 (21) : 3061 - 3066
  • [2] CASTLEMAN B, 1956, CANCER-AM CANCER SOC, V9, P822, DOI 10.1002/1097-0142(195607/08)9:4<822::AID-CNCR2820090430>3.0.CO
  • [3] 2-4
  • [4] HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma
    Dupin, N
    Diss, TL
    Kellam, P
    Tulliez, M
    Du, MQ
    Sicard, D
    Weiss, RA
    Isaacson, PG
    Boshoff, C
    [J]. BLOOD, 2000, 95 (04) : 1406 - 1412
  • [5] KARCHER DS, 1995, NEW ENGL J MED, V333, P797
  • [6] KELLER AR, 1972, CANCER-AM CANCER SOC, V29, P670, DOI 10.1002/1097-0142(197203)29:3<670::AID-CNCR2820290321>3.0.CO
  • [7] 2-#
  • [8] Multicentric Castleman's disease representing effusion at initial clinical presentation: clinicopathological study of seven cases
    Kojima, M.
    Nakamura, N.
    Tsukamoto, N.
    Yokohama, A.
    Itoh, H.
    Kobayashi, S.
    Kashimura, M.
    Masawa, N.
    Nakamura, S.
    [J]. LUPUS, 2011, 20 (01) : 44 - 50
  • [9] Clinical implications of idiopathic multicentric Castleman disease among Japanese: A report of 28 cases
    Kojima, Masaru
    Nakamura, Naoya
    Tsukamoto, Norihumi
    Otuski, Yoshiro
    Shimizu, Kazuhiko
    Itoh, Hideaki
    Kobayashi, Satsuki
    Kobayashi, Hiroshi
    Murase, Takuhei
    Masawa, Nobuhide
    Kashimura, Makoto
    Nakamura, Shigeo
    [J]. INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY, 2008, 16 (04) : 391 - 398
  • [10] Castleman disease and associated autoimmune disease
    Muskardin, Theresa W.
    Peterson, Bruce A.
    Molitor, Jerry A.
    [J]. CURRENT OPINION IN RHEUMATOLOGY, 2012, 24 (01) : 76 - 83